Peptide API Manufacturer

Shenzhen Mingkang Biotechnology Co., Ltd. is a high-tech enterprise specializing in the R&D and production of peptide active pharmaceutical ingredients (APIs) and related products. Headquartered in the Honghuagang Medical and Health Industrial Park, Zunyi City, Guizhou Province, the company has experienced rapid growth while consistently prioritizing technological innovation. Core Business Focus The company's core business centers on peptide APIs, with a strategic emphasis on the GLP-1 series—globally recognized as a key component in diabetes and obesity treatments. This focus has been the primary driver of its commercial success and market expansion. Key Operational Areas Core Business Research, development, and production of peptide active pharmaceutical ingredients (APIs), specializing in GLP-1 series treatments for diabetes and obesity. Product Portfolio GLP-1 series APIs, cosmetic peptides (e.g., acetyl hexapeptide-8, palmitoyl tetrapeptide-7), and custom peptide synthesis services. Technical Strengths Self-optimizing production processes enhance product quality and yield while reducing costs. Proactively building a large-scale innovative peptide library to accelerate drug R&D. Production and Capacity Operations A 3,700-square-meter pilot-scale facility. A new plant scheduled to commence operations in early 2026, targeting a fivefold increase in production capacity. Market and Sales Products exported to North America, Europe, and Southeast Asia. Sales exceeded RMB 100 million from January to September 2025. Global Reach and Future Outlook With exports to major international markets including North America, Europe, and Southeast Asia, our company is poised for significant growth. The upcoming 2026 production facility expansion will further strengthen its global supply capabilities and support its vision to become a leading innovator in the peptide pharmaceutical industry.